site map  

QUESTIONS?

+1 (802) 878-1777

hti@haemtech.com

ORDERING

Human Proteins

Bovine Proteins

Mouse Proteins

Other Species

Inhibitors

Substrates

Antibodies

Sample Collection Tubes

Deficient Plasmas

Assay Kits

Pricing

HOME PAGE

QUESTIONS?

+1 (802) 878-1777

hti@haemtech.com

 Human Coagulation Factor XII

DOMAIN STRUCTURE OF FACTOR XII The organization of the factor XII domain structure based on sequence homology is represented, where: EGF=epidermal growth factor, Type I and Type II=domains homologous to those found in fibronectin, solid arrows=kallikrein cleavage sites that form a- and β-factor XIIa, dashed arrows=cleavages leading to intermediate forms of factor XIIa.

PURCHASING AND PRODUCT INFORMATION

Catalog Number HCXII-0155	Description Human Factor XII	Size 100 µg	Formulation 50% (vol/vol) glycerol/H2O
Storage -20oC	Purity >95% by SDS-PAGE	Activity Determination Clotting assay	Shelf Life (properly stored) 12 months
	Sample Gel Information: Gel: Novex 4-12% Bis-Tris Load: Human Factor XII, 1 µg per lane Buffer: MOPS Standard: SeeBluePlus 2; Myosin (191 kDa), Phosphorylase B (97 kDa), BSA (64 kDa), Glutamic Dehydrogenase (51 kDa), Alcohol Dehydrogenase (39 kDa), Carbonic Anhydrase (28 kDa), Myoglobin Red (19 kDa), Lysozyme (14 kDa)
U.S. Pricing	Product inquiry	SAMPLE DATA SHEET	ORDER NOW!

Overview of Factor XII

Factor XII (XII) (Hageman Factor) is a single chain (Mr=78,000) glycoprotein zymogen that circulates in plasma at a concentration of 40 mg/ml (1-5). Reciprical activation of XII to the active serine protease factor XIIa (XIIa) by kallikrein is central to initiation of the intrinsic coagulation pathway. Surface bound α-XIIa in turn activates factor XI to XIa. Secondary cleavage of α-XIIa by kallikrein yields β-XIIa, which catalyzes solution phase activation of kallikrein, factor VII and the classical complement cascade. 

The ability of a variety of negatively charged substances, both physiological and nonphysiological to promote XII activation and, thus, initiation of the intrinsic pathway has led to the psuedonym "contact activation". Binding to anionic surfaces induces a conformational change, making the XII zymogen more susceptible to cleavage by a variety of proteases (6,7). It is unlikely that binding to negatively charged surfaces alone is sufficient to activate XII, since highly purified preparations of XII and plasma deficient in prekallikrein and high molecular weight kininogen do not undergo this "autocatalysis" (8-11). 

A single cleavage by kallikrein at R353-Val354 of XII yields α-XIIa, a 2 chain protease (Mr=80,000) held together by disulfide bonds. The COOH-terminal light chain (Mr=28,000) contains the catalytic triad (His-40, Asp-89, Ser-191), while the NH₂-terminal heavy chain (Mr=52,000) conatins the anionic surface binding portion of the molecule. A secondary cleavage of α-XIIa by kallikrein outside the disulfide bond yields β-XIIa (XII_f, BHFa, HF_f, hageman factor fragments) (Mr=28,000), which no longer binds anionic surfaces (12). β-XIIa can activate prekallikrein, but has little procoagulant activity (13,14). Several other minor intermediate forms of XIIa are indicated in the figure above. 

Inhibitors of XIIa include C1-INH, α2-antiplasmin, α2-macroglobulin and antithrombin III. At physiological concentrations, the relative effectiveness of these inhibitors is 91 : 4.5 : 3 : 1.5, respectively (10, 16-19). The ratio of C1-INH to XII has been implicated in the "cold activation" of factor VII and the conversion of prorenin to renin on storage of plasma (20,21). 

Human factor XII is prepared from fresh frozen plasma by immunoaffinity chromatography and supplied in 50% glycerol for storage at -20^oC. 

Properties of Factor XII

PURCHASING AND PRODUCT INFORMATION

References 
1. Schmaier, A.H., et al., in Hemostasis and Thrombosis, ed. R.W. Colman, J. Hirsh, V.J. Marder and E.W. Salzman, pp 18-38, J.B. Lippincott Company, Philadelphia, 1987. 
2. Griffin, J.H. and Cochrane, C.G., Methods Enzymol., 45, 56-65 (1976). 
3. Saito, H., et al., J Lab Clin., 88, 506 (1976). 
4. McMullen, B.A. and Fujikawa, N., J. Biol. Chem., 260, 5328 (1985). 
5. Davie, E.W., in Hemostasis and Thrombosis, ed. R.W. Colman, J. Hirsh, V.J. Marder and E.W. Salzman, pp 242-267, J.B. Lippincott Company, Philadelphia, 1987. 
6. Griffin, J.H., Proc. Natl. Acad. Sci. USA, 75, 1998 (1978). 
7. McMillin, L.R., et al., J. Clin. Invest., 54, 1312 (1974). 
8. Revak, S.D., et al., J. Clin. Invest., 59, 1167 (1977). 
9. Fujikawa, K., et al., Biochemistry, 16, 4182 (1977). 
10. Bonno, N., et al., in New Comprehensive Biochemistry, ed. R.F.A. Zwaal and H.C.Hemker, pp. 103-128, Elsevier, Amsterdam, 1986.
11. Claeys, H. and Collen, D. (1978) Eur. J. Biochem., 87, 69 (1978). 
12. Revak, S.D. and Cochrane, C.G., J. Clin. Invest., 57, 852 (1976). 
13. Cochrane, C.G., et al., J. Exp. Med., 138, 1564 (1973). 
14. Revak, S.D., et al., J. Exp. Med., 147, 719 (1978). 
15. Ghebrehiwet, B., et al., J. Clin. Invest., 71, 1458 (1983).
16. DeAgostini, A., et al., J. Clin. Invest., 73, 1542 (1984). 
17. Rathoff, O.D., et al., J. Exp. Med., 129, 315 (1969). 
18. Stead, N., et al., J. Biol Chem., 251, 6481 (1976). 
19. Pixley, R.A., et al., J. Biol Chem., 260, 1723 (1985). 
20. Gjonnass, H., Thromb. Diath. Haemorrh., 28, 182 (1972). 
21. Radcliffe, R., et al., Blood, 59, 611 (1977).